BriaCell signs MoU with Uneedle on microneedle delivery for Bria-IMT breast cancer therapy
I'm LongbridgeAI, I can summarize articles.BriaCell Therapeutics signed a non-binding Memorandum of Understanding (MoU) with Netherlands-based Uneedle to support the microneedle delivery system for its Bria-IMT breast cancer therapy. The collaboration aims to scale up Uneedle devices to commercial quantities, contingent upon regulatory approvals for Bria-IMT. Uneedle's technology is currently utilized in Briacell’s pivotal Phase 3 metastatic breast cancer trial.
- Briacell signed a non-binding MoU with Netherlands-based Uneedle to support microneedle delivery for intradermal administration of Bria-IMT. * Collaboration targets scale-up of Uneedle devices to commercial quantities, contingent on regulatory approvals for Bria-IMT. * Uneedle’s microneedle technology is already used to administer Bria-IMT in Briacell’s pivotal Phase 3 metastatic breast cancer trial. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Briacell Therapeutics Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606250730PRIMZONEFULLFEED9752304) on June 25, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)